Meet the THIN platform — prescription-only compounded semaglutide and tirzepatide oral sprays, built for eligible patients transitioning off injectable GLP-1 therapy.
Prescription-only. Compounded medication. Not FDA-approved. Provider review required. Dispensed only if medically appropriate.
Research shows many patients regain a significant share of lost weight within a year of stopping a GLP-1 — often cited around 60–70% within 12 months — as appetite signaling returns. Obesity behaves like a chronic, relapsing condition. The THIN platform is built for the maintenance phase that follows.
Same easy sublingual format. Your provider helps determine which is right for you.
The THIN platform delivers its active ingredient as a sublingual spray under the tongue — designed to absorb through the oral mucosa instead of being swallowed and broken down in the stomach.
Fill out a quick, free medical history form so your provider can build the right plan for you.
Connect with a licensed physician or nurse practitioner through a simple online conversation.
If appropriate, your compounded medication ships to your door with free shipping.
Explore the THIN platform and see which needle-free, prescription-only maintenance option may be right for you.
Explore the Lineup